• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Combination therapy comparable to high-intensity statins for LDL cholesterol

byNicholas WoolfandAimme Li, MD
February 11, 2014
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. A mid-intensity statin plus ezetimibe lowered LDL-C more than high-intensity statin monotherapy in patients with either atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM).

2. A low-intensity statin plus bile acid sequestrant lowered LDL-C more than mid-intensity statin monotherapy in patients with hyperlipidemia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The new recently released guidelines for treatment of high cholesterol by the ACC/AHA emphasize long-term statin therapy as the best therapeutic strategy to reduce both LDL-C and prevent ASCVD progression. However, these guidelines do not adequately address the therapeutic options for patients who are intolerant of statins. This systematic review found that mid-intensity statin plus ezetimibe combination therapy reduces LDL-C 5% to 15% and 3% to 21% more than high-intensity statin monotherapy among patients with ASCVD and DM, respectively. It also showed that low-intensity statin plus bile acid sequestrant lowered LDL-C 0% to 14% more than mid-intensity statin monotherapy in patients with hyperlipidemia. There was insufficient evidence to examine the effect of adding a bile acid sequestrant in patients with ASCVD or DM. There was also insufficient data available to compare drug regimens including fibrates, niacin or omega-3 fatty acids against statin monotherapy.

This study was limited in that it could not compare the drug regimens’ long-term clinical outcomes, adherence rates or adverse event occurrence. This happened because the desired information was not provided in the RCTs reviewed by the authors and because none of the trials included in the review lasted longer than one year. Also, none of the selected trials examined patients with statin intolerance. This study uncovered the possible benefits of statin combination therapy with either bile acid sequestrants or ezetimibe for patients who cannot tolerate high-intensity statin monotherapy, but it also clearly highlights the need for more trials comparing the long-term clinical benefits, adherence and harms of these different LDL-lowering therapeutic regimens.

RELATED REPORTS

Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis

Click to read the study in the Annals of Internal Medicine

Relevant Reading: A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough

In-Depth [systematic review]: The authors searched several medical journal databases, references of pertinent review articles and studies on ClinicalTrials.gov for randomized, controlled trials that fit their predetermined eligibility criteria. These criteria targeted trials including adult patients with a LDL-C level at or above 190 mg/dL that compared statin monotherapy with a combination therapy in these patients. The strength of evidence (SOE) of each trial was assessed by evaluating the sources of bias, consistency of results and precision. No studies were found that compared statin plus bile acid sequestrant to statin monotherapy in patients with ASCVD or DM, but in patients with hyperlipidemia, the combination therapy lowered LDL-C 0% to 14% more than monotherapy (moderate SOE). Analysis of studies comparing combination therapy with statin plus ezetimibe to statin monotherapy in patients with ASCVD found that the combination therapy decreased LDL-C 5% to 15% more than the statin monotherapy (moderate SOE). Among patients with DM, combination therapy lowered LDL-C 3% to 21% more than statin monotherapy (moderate SOE). There were no statistically significant differences in treatment adherence or adverse event occurrence observed in any of the trial analyses.

More from this author: New ACC/AHA cholesterol guidelines emphasize the appropriate-level statin treatment, Healthier lifestyle linked with longer telomeres in benign prostate cancer, Among HIV-positive infants, early protease inhibitor-based treatment effective, MERS remains poorly understood, deadly

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: cholesterolstatins
Previous Post

2 Minute Medicine Rewind February 3 – 10, 2014

Next Post

Community health workers improve outcomes in low socioeconomic status patients (IMPaCT)

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans

June 26, 2025
Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients

June 10, 2025
CT texture analysis may predict liver insufficiency after hepatectomy
Pharma

Mirum: Ctexli reduces cholesterol metabolite build-up in patients with cerebrotendinous xanthomatosis

April 15, 2025
Provision of medically-tailored meals linked with lower admissions and medical spending
Chronic Disease

Time-restricted eating may improve glycemic control in patients with metabolic syndrome

September 30, 2024
Next Post
Community health workers improve outcomes in low socioeconomic status patients (IMPaCT)

Community health workers improve outcomes in low socioeconomic status patients (IMPaCT)

Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma

Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma

Gestational weight loss may improve outcomes for obese women

Peer based health education program linked to reduced waist circumference

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.